Crizotinib in ROS1-rearranged non-small-cell lung cancer.

By A. Shaw, Sai-Hong Ignatius Ou, Y. Bang, Ross D. Camidge, Benjamin J. Solomon, Ravi Salgia, Gregory Riely, Marileila Varella-garcia, Geoffrey I. Shapiro, D. Costa and 12 more. New England Journal of Medicine, 2015

608 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/2dde562b5e857dfaad5df031e96acd2666deb2a9

Citations in the corpus

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, unknown): “On the basis of the available preclinical data, the phase I PROFILE 1001 study of crizotinib was amended to include patients with ROS1-rearranged NSCLC in the expansion cohort [216].”
• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018, unknown): “High objective tumour response rates were demonstrated with these drugs in ROS1-rearranged NSCLC in a series of single arm studies [19, 20].”